Investigating the effect of memantine for the treatment of obsessions in bipolar patients

The effect of memantine with a dose of 20 mg for the treatment of obsessions in bipolar patients with a fixed regimen of quetiapine and lithium

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240601061976N1

Enrollment

Registered

2024-06-05

Start date

2024-06-21

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar. Bipolar disorder

Interventions

Intervention 1: Intervention group: In addition to routine bipolar treatment, 10 mg (Shafa Company) Memantine tablets as one tablet after a detailed history and confirmation of the patients obsession.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age range 18-65 Bipolar patients with obsessive compulsive comorbidity Consent of the patient's guardian

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Obsession score. Timepoint: Before the intervention, 3, and 6 weeks after the intervention. Method of measurement: According to DSM-5 criteria.;Side effects of memantine. Timepoint: During the study, 3, and 6 weeks after the intervention. Method of measurement: Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamzeh Rostami

Ahvaz University of Medical Sciences

Rostami_h@ajums.ac.ir+98 61 3311 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026